thrombosis

Hemodialysis Associated to Higher Incidence of In Stent Thrombosis

Original title:&nbsp;Impact of hemodialysis on local vessel healing and thrombus formation after drug-eluting stent implantation.&nbsp;Reference:&nbsp;Akihide Konishi, et al. &nbsp;Journal of Cardiology 2014;64:25-31 &nbsp; Even though the benefit of DES implantation to the general population is undeniable, it has been proved lower in hemodialysis patients (HD); the reason behind this phenomenon remains unclear. 121 patients received<a href="https://solaci.org/en/2014/08/08/hemodialysis-associated-to-higher-incidence-of-in-stent-thrombosis/" title="Read more" >...</a>

Thrombosis with bioresorbable scaffolds: the story of DES all over again?

Original title:&nbsp;Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry.&nbsp;Reference:&nbsp;Capodanno D et al. EuroIntervention. 2014 Jul 18. Epub ahead of print &nbsp; The GHOST-EU registry, that included 1189 patients from 10 European centers between 2011 and 2014, is now the largest registry<a href="https://solaci.org/en/2014/07/30/thrombosis-with-bioresorbable-scaffolds-the-story-of-des-all-over-again/" title="Read more" >...</a>

Reduced risk of acute, late and very late thrombosis with new generations of DES versus BMS in the acute myocardial context

Original title:&nbsp;Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR.&nbsp;Reference:&nbsp;Sarno G et al. J Am Coll Cardiol. 2014;Epub ahead of print. This study evaluated 34147 consecutive patients suffering acute myocardial infarction with ST-segment elevation included in the SCAAR registry (Swedish Coronary Angiography and Angioplasty Registry) undergoing primary<a href="https://solaci.org/en/2014/07/11/reduced-risk-of-acute-late-and-very-late-thrombosis-with-new-generations-of-des-versus-bms-in-the-acute-myocardial-context/" title="Read more" >...</a>

Ticagrelor reduces in-stent thrombosis in patients with acute coronary syndromes

Original title:&nbsp;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: An analysis from the prospective randomized PLATO trial.&nbsp;Reference:&nbsp;Steg PG et al. Circulation. 2013; Epub ahead of print The PLATO study randomized 18624 patients with acute coronary syndrome to receive ticagrelor &nbsp; (180 mg loading dose followed by 90 mg twice daily )<a href="https://solaci.org/en/2013/09/12/ticagrelor-reduces-in-stent-thrombosis-in-patients-with-acute-coronary-syndromes/" title="Read more" >...</a>

Rivaroxaban reduces in-stent thrombosis in patients with acute coronary syndromes

Original title:&nbsp;Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51.&nbsp;Reference:&nbsp;C. Michael Gibson et al. J Am Coll Cardiol 2013;62:286&ndash;90. There are few contemporary studies that investigated oral anticoagulation utility in patients with acute coronary syndromes and coronary angioplasty. Rivaroxaban is an oral anticoagulant that directly and<a href="https://solaci.org/en/2013/08/23/rivaroxaban-reduces-in-stent-thrombosis-in-patients-with-acute-coronary-syndromes/" title="Read more" >...</a>

Double DES in bifurcations, double thrombosis risk

Original title:&nbsp;Late Thrombosis After Double Versus Single Drug-Eluting Stent in the Treatment of Coronary Bifurcations A Meta-analysis of Randomized and Observational Studies.&nbsp;Reference:&nbsp;Marco Zimarino et al. J Am Coll Cardiol Intv 2013. Article in press. In the era of drug-eluting stents, (DES), several randomized and observational studies have been conducted trying to find the best strategy<a href="https://solaci.org/en/2013/06/14/double-des-in-bifurcations-double-thrombosis-risk/" title="Read more" >...</a>

Stent Thrombosis in the Real World 

Original title:&nbsp;Incidence and predictors of stent trombosis: a single-centre study of 5833 consecutive patients undergoing coronary artery stenting&nbsp;Reference:&nbsp;Javaid Iqbal et al. EuroInterventional 2013;9:62-69 Though potentially fatal, stent thrombosis is a low frequency event associated to stent malapposition, fractures, resistance to antiplatelet therapies, and diseases such as diabetes and kidney disease, among other factors. 5883 pacients<a href="https://solaci.org/en/2013/05/31/stent-thrombosis-in-the-real-world/" title="Read more" >...</a>

Future strategies to prevent restenosis and stent thrombosis

Original title:&nbsp;Endothelial cell repopulation after stenting determines in-stent neointima formation: effects of bare-metal vs. drug-eluting stents and genetic endothelial cell modification.&nbsp;Reference:&nbsp;Douglas G et al. European Heart Journal doi:10.1093/eurheartj/ehs240 Experimental models of vascular injury have shown that the rate of endothelial cell repopulation post-injury is a critical factor in determining subsequent neointima formation as well as<a href="https://solaci.org/en/2012/12/04/future-strategies-to-prevent-restenosis-and-stent-thrombosis/" title="Read more" >...</a>

Risk score of thrombosis in patients with acute coronary syndrome

Original title:&nbsp;Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes.&nbsp;Reference:&nbsp;George D. Dangas et al. J Am Coll Cardiol Intv 2012;5:1097&ndash;105. The implantation of a stent in a pro thrombotic condition such as acute coronary syndrome (ACS) is associated with a higher incidence of stent thrombosis.&nbsp; There is no data<a href="https://solaci.org/en/2012/11/23/risk-score-of-thrombosis-in-patients-with-acute-coronary-syndrome/" title="Read more" >...</a>

IAM y múltiples vasos, ¿podemos realizar un solo procedimiento?

Initial Complete Revascularization vs. Staged Revascularization in Patients with STEMI and Multivessel Disease

In patients with ST-segment elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (primary PCI), multivessel disease is observed in up to 40% of cases. The optimal timing for revascularizing non-culprit lesions in these patients without cardiogenic shock remains a controversial issue. European guidelines recommend completing revascularization during the initial procedure or within 45&nbsp;days<a href="https://solaci.org/en/2024/07/17/initial-complete-revascularization-vs-staged-revascularization-in-patients-with-stemi-and-multivessel-disease/" title="Read more" >...</a>

Top